What are Somatostatin receptor agonist drugs?

Somatostatin receptor agonist drugs are pharmacologic agents that share a common mechanism (typically targeting Somatostatin receptors (SSTR2, SSTR5)). 3 are currently marketed, with 4 more in clinical development.

What are the marketed Somatostatin receptor agonist drugs?

Marketed Somatostatin receptor agonist drugs include Somatostatin analog, Copper Cu 64 Dotatate, Signifor (pasireotide).

Somatostatin receptor agonist

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

3 marketed 4 in Phase 3

This page covers all Somatostatin receptor agonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Somatostatin receptors (SSTR2, SSTR5), Somatostatin receptor 2 (SSTR2), Somatostatin receptors (SSTR1, SSTR3, SSTR5).

Targets

Somatostatin receptors (SSTR2, SSTR5) · Somatostatin receptor 2 (SSTR2) · Somatostatin receptors (SSTR1, SSTR3, SSTR5) · Somatostatin receptors (SSTR) · Somatostatin receptor 2 (SSTR2); somatostatin receptors

Marketed (3)

Somatostatin analog · The Netherlands Cancer Institute · Oncology
Somatostatin analogs bind to somatostatin receptors on neuroendocrine tumor cells and other tissues, inhibiting hormone secretion and slowing tumor growth.
Copper Cu 64 Dotatate · Vanderbilt-Ingram Cancer Center · Oncology
Copper Cu 64 Dotatate is a radioactive imaging agent that binds to somatostatin receptors on neuroendocrine tumor cells, allowing PET visualization and localization of these tumors.
Signifor (pasireotide) · Zealand University Hospital · Endocrinology
Pasireotide is a somatostatin receptor agonist that binds to multiple somatostatin receptor subtypes to suppress hormone secretion and inhibit tumor growth.

Phase 3 pipeline (4)

177Lu-DOTA0-Tyr3-Octreotate · Advanced Accelerator Applications · Oncology
177Lu-DOTA0-Tyr3-Octreotate is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy.
IPN10200 · Ipsen · Oncology
IPN10200 is a somatostatin receptor agonist that binds to somatostatin receptors to inhibit hormone secretion and tumor growth.
68Ga-DOTATOC · Montefiore Medical Center · Oncology; Nuclear Medicine/Diagnostic Imaging
68Ga-DOTATOC is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells, enabling their detection and localization via positron emission tomography (PET) imaging.
177Lu-edotreotide · Grupo Espanol de Tumores Neuroendocrinos · Oncology
177Lu-edotreotide is a radioligand therapeutic that binds to somatostatin receptor 2 (SSTR2) on neuroendocrine tumor cells and delivers targeted radiation to kill them.

Patent intelligence

somatostatin receptor agonist patent landscape — aggregated cliff calendar, attackable patents, originator estates